updated 4/5/2011 7:17:20 AM ET 2011-04-05T11:17:20

DALLAS, April 5, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Orexigen Therapeutics Inc. (Nasdaq:OREX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/OREX

Orexigen Therapeutics Inc. (OREX) is a biopharmaceutical company focused on the treatment of obesity. Its lead product candidates reflect a growing understanding of how the central nervous system (CNS) regulates appetite and metabolism as well as the mechanisms that limit weight loss over time. OREX's lead combination product candidates targeted for obesity are Contrave, which has completed phase III clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application, and Empatic, which has completed phase II clinical development. The Company is currently in the process of determining the next steps for Contrave.

This newsletter has been helping traders make great investment decisions on OREX; click here for a 25% discount offer.

In the report, the analyst notes:

"OREX shares got a boost Monday after the obesity drug developer announced additional data showing overweight and obese patients treated with Contrave maintained normal 24-hour circadian patterns over one year of treatment."

"The observation that patients in this sub-study maintained normal circadian variation of blood pressure may be particularly relevant since a loss of the nocturnal lowering in blood pressure may predict a poor cardiovascular outcome," Jorge Plutzk M.D., director of the Vascular Disease Prevention Program at Brigham and Women's Hospital, said in a press release."

To read the entire report visit: www.microstockprofit.com/lp/OREX

See what investors are saying about OREX at http://www.stockhideout.com

Get breaking news on OREX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com